Drug intelligence / Profile preview

ACTIGEN

Development stage: Unknown
Lead developer: Sanara MedTech
Administration: Topical

Overview

ACTIGEN (also known as ACTIGEN Verified Inductive Bone Matrix) is a naturally derived allograft bone matrix developed by Sanara MedTech and distributed in partnership with InfuSystem. It is designed for use in the surgical market, specifically for orthopedic and spinal fusion procedures. The product is processed using proprietary methods to preserve native bone morphogenetic proteins (BMPs), providing it with osteoinductive properties that signal bone-forming cells. Additionally, it serves as an osteoconductive scaffold to support the physical growth of new bone. ACTIGEN is characterized by its robust handling properties and is classified as a biologic medical device intended to facilitate bone repair and regeneration.

Brand names: ACTIGENACTIGEN Verified Inductive Bone Matrix
Other names: Actigen

Targets

FimH (Type 1 fimbrial adhesin)

Beyond the preview

Go deeper on ACTIGEN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACTIGEN.

Explore the full profile